Myasthenia gravis (MG) is a rare, chronic, autoimmune, neuromuscular condition where the body’s immune system mistakenly targets the connection between the nerves and the muscles. In people living with MG, voluntary muscles don’t respond well to the signals sent by the brain. The main symptoms are extreme muscle weakness and fatigue.
Additionally, the severity of muscle weakness worsens over time, an event called muscle ‘fatigability’, and on rare occasions the weakness can be life-threatening, when people lose the ability to swallow or to breathe. Since the actual symptoms of MG vary greatly, individuals experience the disease in a very personal way, which can cause profound uncertainty.
As part of our ongoing commitment to underserved patient populations, UCB is continuing to investigate treatments that can support patients living with myasthenia gravis. Zilucoplan is a small peptide inhibitor of complement component 5 (C5) that we are developing for the treatment of MG, currently in Phase 3. Also in our pipeline is rozanolixizumab, UCB’s investigational humanized monoclonal IgG antibody, which is also in Phase 3.
- 1 https://www.ucb.com/disease-areas/Myasthenia-gravis